MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies (Pharmaceuticals, Drugs, Biotechnology, Biosimilars) _ Neurodegenerative; Neuromuscular, Neuropsychiatric
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX)
Organization & Developments: Catalyst Pharmaceuticals
Parents
Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX)
Children
*Focused on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases
2018: Catalyst Pharma: Is The Post-Approval Doldrums An Opportunity?_seekingalpha.com
2018: Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse® (Amifampridine Phosphate) for Lambert-Eaton Myasthenic Syndromenasdaq
2019: Despite Unexpected Competition From Jacobus, Catalyst Pharmaceuticals Still Has A Solid Business Model_seekingalpha.com
2021: Checking In On Catalyst Pharmaceuticals
2022: Catalyst Pharmaceuticals Ramp May Be Over For Now_seekingalpha.com
2023: Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity
2024: Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch_seekingalpha.com
2024: Catalyst Pharmaceuticals: Agamree Is Its Key To A Sustainable Future
2024: Catalyst Pharmaceuticals: High Valuation Amid Weak Long-Term Prospects (Rating Downgrade)_seekingalpha.com
2024: Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)
2024: Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk_ seekingalpha.com
2024: Catalyst Pharmaceuticals' (NASDAQ:CPRX) Anemic Earnings Might Be Worse Than You Think_ yahoo
2024: With 75% ownership of the shares, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is heavily dominated by institutional owners
2025: Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
2025: Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE_seekingalpha.com
2025: Catalyst: Solid Business Model Propels Growth For This Buy And Build Pharma
2026: Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT Insight
Jumps
Finance & Acquisitions: Catalyst Pharmaceuticals
Key People: Catalyst Pharmaceuticals